Intelligence for the Dealmaking Community since 1965
Intelligence for the Dealmaking Community since 1965
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
This is premium content

To read the full story, please upgrade your plan.

Upgrade plan
Login to your account

Pfizer

image
Healthcare
Ozempic Challengers, Immunology Firms Line Up for Rebound in M&A
Drugmakers have been focused on buying late-stage assets with larger revenue potential to replace older blockbuster drugs that have fallen out of favor.
January 8, 2024
image
Healthcare
Merck KGaA Buys Exelead for $780M
Merck is seeking to capitalize on the success of mRNA vaccines, the technology behind the Covid-19 inoculations.
January 6, 2022
image
Healthcare
Pfizer Purchases Arena in $6.7B Deal
Pfizer plans to speed up clinical development of etrasimod, Arena’s experimental treatment for immuno-inflammatory diseases.
December 13, 2021
image
Strategic Owners
Johnson & Johnson to Split into Two Companies
J&J’s decision comes just days after General Electric said it would break itself into three pieces.
November 12, 2021

Trending

1.
Middle-Market M&A Finally Finds Its Footing
July 9, 2026
2.
Secondaries Edge: CVs Come of Age—and Under Scrutiny
July 8, 2026
3.
PE-Backed Pye-Barker Fire & Safety Purchases ResponseTECH
July 9, 2026
4.
Secondaries Edge: Smaller Sponsors, Sovereign Sellers and Tougher Standards
July 22, 2026
5.
War Tech Ignites M&A
July 13, 2026
6.
Inside the Lower Middle Market’s Two-Track Deal Sourcing Strategy
July 20, 2026
7.
PE’s Next Bet: Buy Companies That Need Work
July 15, 2026
8.
Morgan Stanley Expects Record $6.4T Global M&A Market in 2026
July 9, 2026
9.
Why LPs Are Still Committing to Some LMM Funds
July 14, 2026